Kobo Biotech Ltd
NSE: BSE: 531541
₹2.97
(4.95%)
Wed, 27 May 2026, 06:04 pm
Market Cap67.42M
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KKobo Biotech Analysis
dividend
- Unable to calculate sustainability of dividends as Avon Lifesciences has not reported any payouts.
- Unable to evaluate Avon Lifesciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Avon Lifesciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Avon Lifesciences's cash and other short term assets cover its long term commitments.
- Avon Lifesciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not well covered by operating cash flow (8.2%, less than 20% of total debt).
- Avon Lifesciences has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Irrelevant to check if Avon Lifesciences's debt level has increased considering it has negative shareholder equity.
- Avon Lifesciences has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- High level of physical assets or inventory.
management
- The tenure for the Avon Lifesciences board of directors is about average.
- The average tenure for the Avon Lifesciences management team is less than 2 years, this suggests a new team.
misc
- Avon Lifesciences is not covered by any analysts.
- Avon Lifesciences has significant price volatility in the past 3 months.
past
- Unable to compare Avon Lifesciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Avon Lifesciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Avon Lifesciences has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Avon Lifesciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
- It is difficult to establish if Avon Lifesciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Avon Lifesciences's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Avon Lifesciences has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Avon Lifesciences is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Avon Lifesciences is loss making, we can't compare the value of its earnings to the India market.
- 531541 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 531541 underperformed the Market in India which returned -14.5% over the past year.
- BSE:531541 is flat (-0.5%) underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:531541 is flat (-0.5%) underperforming the market in India which returned 8% over the past month.